Lisa Licitra
丽莎·利西特拉
MD
Head, Head and Neck Medical Oncology Unit; Full Professor of Medical Oncology, University of Milan头颈部肿瘤内科主任，米兰大学医学肿瘤学正教授
👥Biography 个人简介
Lisa Licitra, MD is Head of the Head and Neck Medical Oncology Unit at the Fondazione IRCCS Istituto Nazionale dei Tumori (INT) in Milan and Full Professor of Medical Oncology at the University of Milan. She is one of Europe's most prominent head and neck oncologists and has been a central figure in EORTC, ESMO, and EHNS clinical research for over two decades. Dr. Licitra has led or been a principal investigator in numerous European and global HNSCC trials, including studies of induction chemotherapy with TPF (docetaxel-cisplatin-fluorouracil), cetuximab-based regimens, and immunotherapy combinations. She has contributed key analyses on the prognostic and predictive role of HPV in European HNSCC populations and has been instrumental in developing ESMO Clinical Practice Guidelines for HNSCC that are widely used across Europe. Dr. Licitra is a Past President of the European Head and Neck Society (EHNS) and has served as chair of multiple ESMO guideline working groups. She is a leading voice for multidisciplinary tumor board approaches and has championed patient-reported outcomes in HNSCC clinical trials.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
TPF Induction Chemotherapy in Locally Advanced HNSCC
Participated in European trials establishing TPF (docetaxel, cisplatin, 5-fluorouracil) induction chemotherapy as superior to PF (cisplatin-5-fluorouracil) regimens in locally advanced HNSCC, and contributed to international consensus on the role and limitations of induction approaches prior to definitive chemoradiation.
ESMO HNSCC Clinical Practice Guidelines
Led or co-chaired successive ESMO Clinical Practice Guidelines for squamous cell carcinoma of the head and neck, providing European oncologists with evidence-based treatment algorithms across locoregional and recurrent/metastatic disease settings, regularly updated to incorporate new immunotherapy and targeted therapy data.
HPV Epidemiology in European HNSCC Populations
Conducted large-scale analyses characterizing the prevalence and prognostic impact of HPV infection in European head and neck cancer cohorts, demonstrating geographic and anatomic site variability in HPV positivity rates and validating p16 as a surrogate marker in European patients.
Multidisciplinary Management and Quality of Life in HNSCC
Championed the integration of patient-reported outcomes, speech and swallowing function assessment, and quality-of-life endpoints in HNSCC clinical trials, advocating for toxicity-guided treatment decisions particularly in organ preservation strategies.
Representative Works 代表性著作
Head and Neck Cancers: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Annals of Oncology (2022)
Comprehensive ESMO guideline providing European evidence-based recommendations for management of all head and neck cancer subsites, regularly updated.
Effect of Cetuximab Combined with Cisplatin or Carboplatin on Survival in Patients with Platinum-Refractory Recurrent or Metastatic HNSCC
Journal of Clinical Oncology (2012)
Analysis of cetuximab plus platinum re-challenge outcomes in platinum-refractory HNSCC, defining the utility and limits of EGFR-targeted salvage regimens.
Human papillomavirus in head and neck cancer: prevalence, molecular trends and impact on outcomes
Annals of Oncology (2016)
Review of HPV epidemiology and prognostic impact in European HNSCC populations with implications for treatment stratification and de-escalation trial design.
Docetaxel plus cisplatin and fluorouracil versus cisplatin and fluorouracil in head and neck cancer
New England Journal of Medicine (2007)
TAX323 trial demonstrating TPF superiority over PF induction chemotherapy in locally advanced unresectable HNSCC, establishing TPF as the preferred induction regimen.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-04-06 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 丽莎·利西特拉 的研究动态
Follow Lisa Licitra's research updates
留下邮箱，当我们发布与 Lisa Licitra（Fondazione IRCCS Istituto Nazionale dei Tumori (INT), Milan）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment